Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.
One Sansome Street, Suite 3630 San Francisco, CA 94104
920 Broadway 16th floor New York, NY 10010
Bradley Bolzon
Managing Director
Gianni Gromo
Partner
Thomas Hudson Ph.D
Venture Partner
Katharina Kreymborg Ph.D
Principal
Bill Link
Investor
Guido Magni
Partner
Charles Warden
Managing Director
Tom Woiwode
Managing Director
Rami Hannoush Ph.D
Venture Partner
Clare Ozawa
Managing Director
Past deals in Ottawa
Turnstone Biologics
Series D in 2021
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.
Turnstone Biologics
Series B in 2016
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.
Turnstone Biologics
Series A in 2015
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.